Company intelligence / Profile preview
iosBio
Burgess Hill / Haywards Heath, West Sussex, United Kingdomiosbio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
iosBio’s lead program is an oral Epstein-Barr virus vaccine with preclinical data showing robust mucosal and systemic immunity. The company’s oral COVID‑19 vaccine has entered clinical trials. Their proprietary OraPro platform enables thermostable oral delivery of vaccines as tablets or capsules that do not require cold chain logistics and can be self-administered. Additional programs include an oral influenza vaccine in preclinical studies (“FluVid”) and several others in discovery.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Oral vaccines (non-replicating viral vector vaccines)biopharmaceuticals
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on iosBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iosBio.